Aficamten — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for hypertrophic cardiomyopathy.
This complimentary MARA Rating® report evaluates Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). The therapy received a MARA Score of 2.68 out of 4, corresponding to a Marginal (B++) rating. In comparison, the cardiology 5-year average is 3.1 and the overall industry 5-year average is 3.0, positioning Aficamten below both benchmarks.
Clinical Effectiveness: A+ (Very Strong)
Evidence from Phase 2 and Phase 3 trials, including the pivotal _SEQUOIA-HCM_ study, showed significant improvements in key endpoints. These included reductions in left ventricular outflow tract (LVOT) gradient and enhanced exercise capacity. The primary endpoint of peak VO₂ increase was achieved with clinical meaningfulness, and all secondary endpoints met statistical significance, highlighting a strong advantage over standard care.
Comparator Selection: A+ (Very Strong)
Trials included both placebo plus background therapy and an active comparator, metoprolol. These comparators align with current standards for obstructive HCM, ensuring that the results are relevant to real-world practice.
Care-Pathway Integration: A (Strong)
Aficamten fits logically into existing treatment strategies for obstructive HCM without requiring new diagnostic technologies. Monitoring needs are manageable, supporting its practical use within current healthcare delivery systems.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk—clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more—each scored on a seven-level scale (A++ to C). We then apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and potential reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains: Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty. Available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or send us an email at: sales@mararating.com to learn more and unlock your access.
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer in mararating.com
Access this report and hundreds of others here: https://mararating.com/mara-ratings-list.